Clinical landscape dominated by ADCs with more than half with TOP1 payloads. Need for different payloads to address cross-resistance. Insightful presentation ⁦G Curigliano MD PhD⁩ #ESMObreast2024 #bcsm

Excellent presentation by ⁦Komal Jhaveri⁩ highlighting detailed safety results related to Dato-DXd vs TPC for HR+ MBC from Tropion-B01 #esmobreast2024 ⁦ #bcsm

Excited to see more emerging SERD data across settings: 2nd line, 1st line w/ CDK 4/6, adjuvant, and adjuvant switch strategies!

#SERD
#clinicaltrials
Sarah Cannon Docs

Personal selection of 30 new (+ new-ish) ADCs that will be presented at #ASCO24 divided by payloads and targets.

Notes:
- Including 'publication only' abstracts
- Not including mainstream ADCs and/or combo
- Not including trial in progress

Tissue agnostic activity of Trastuzumab deruxtecan (T-DXd) in patients with solid tumours harbouring activating HER2 mutations (DESTINY-PanTumor01): primary results LancetOncology G Curigliano MD PhD #bcsm
Full Text link:
sciencedirect.com/science/articl…

TROPION-Breast03: datopotamab deruxtecan ± durvalumab in pts with triple-negative breast cancer and residual invasive disease after neoadjuvant therapy - study design published in TAMO. Trial actively enrolling SWOG Cancer Research Network #bcsm Full text link: journals.sagepub.com/doi/10.1177/17…

.VIRGINIA KAKLAMANI and Aditya Bardia, MD discussed the Phase III Destiny-Breast06 trial, in which TDXd demonstrated improvement in PFS in patients with HR-positive, HER2-low and HER2-ultralow metastatic breast cancer. Watch now on SABCS Snippets:
bit.ly/3JHpw9q
UT Health San Antonio MD Anderson

NEWS FROM INDUSTRY
Results from the DESTINY-Breast06 trial indicate that trastuzumab deruxtecan🧪could become a new standard of care for #HER2 -low 🧬and HER2-ultralow metastatic #BreastCancer patients

➡️showing significant PFS improvements 📈over standard chemotherapy after

Positive results from Destiny B06: T-DXd demonstrated PFS improvement over chemotherapy in the primary and overall trial population (incl HER2-low and ultralow). #bcsm @oncoalert astrazeneca.com/media-centre/p…

Wonderful visit University of Arizona Health Sciences. Thank you Rachna Shroff, MD, FASCO and team at UA Cancer Center for hosting an outstanding symposium and panel discussion Nancy G. Brinker Susan G. Komen Need to expand community engagement to reduce disparities and improve outcomes for pts with cancer.

Pivotal phase 3 clinical trials with Dato-DXd ongoing, including Tropion-B03 enrolling pts with residual disease after neoadjuvant therapy for TNBC. Collaboration SWOG Cancer Research Network Kevin Kalinsky, MD, MS Eva M Ciruelos Dawn Hershman classic.clinicaltrials.gov/ct2/show/NCT05… #bcsm

Out in Journal of Clinical Oncology: Results from Tropion pan-tumor 01. In patients with advanced HR+ BC and TNBC, Dato-DXd (trop2 ADC) demonstrated promising clinical activity and a manageable safety profile. #bcsm OncoAlert Erika Hamilton, MD Full text: ascopubs.org/doi/pdf/10.120…

Excellent presentation at AACR by Rachel Occhiogrosso Abelman, MD on TOP1 mutations mediating cross-resistance to ADCs. Implications for ADC sequencing and drug development in MBC. #bcsm

Out in The Lancet the results of thePHERgain study showing impressive 3-y IDFS rate

A PET-based, pCR-adapted strategy could help identify patients with HER2-positive EBC who could safely omit chemotherapy

OncoAlert

thelancet.com/journals/lance…

Omitting Axillary Dissection in Breast Cancer with Sentinel-Node Metastases | New England Journal of Medicine nejm.org/doi/full/10.10… Continued de-escalation of local therapies in breast cancer.

Thank you Jeffrey peppercorn MD for the advocacy and collaboration JCO Oncology Practice
Link to full text article: ascopubs.org/doi/10.1200/OP…

Anne dedicated the last decade of her life, living w MBC, to advocacy, & made an impact that will remain - & grow! - for years to come.

What an honor to have been by her side from the start of the Patient-Centered Dosing Initiative, & be leading it now.

therightdose.org/in-memoriam

The Right Dose: Patient Advocate–Led Survey out ⁦⁦JCO Oncology Practice⁩. Honoring PCDI’s founder Anne Loeser, for visionary leadership and commitment, this piece is a heartfelt tribute to her legacy following her passing from MBC ⁦Julia Maués⁩ #bcsm ascopubs.org/doi/10.1200/OP…

Powerful address by President Kelly K Hunt #SSO2024
📢 Empowering surgeons 💪🏻 goes through
✨Leadership
✨Mentorship: be a multiplier, not a diminisher
✨Collaboration: bring together pioneers, integrators, drivers & guardians
@mdandersonnews Sandra Wong @drcnclarke @tarikingmd

Thank you for the opportunity to present the #KEYNOTE756 data Society of Surgical Oncology! A potential future clinical practice change!! Stay tuned for the EFS update!! #SSO2024 #bcsm